Compare IDEXX Laboratories, Inc. (IDXX) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Schlumberger NV — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Schlumberger NV trades at $48.9 (market cap $72.69B). The key difference: Schlumberger NV is the larger of the two by market cap, and Schlumberger NV pays a 2.41% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Schlumberger NV for 99 Days on average.
| IDXX | SLB | |
|---|---|---|
Market Cap | $40.43B | $72.69B |
Volume | 692,164 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $766.68 | $60.10 |
52-Week Low | $504.70 | $31.72 |
Typical Hold Time | 46 Days | 99 Days |
Enterprise Value | $41.32B | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
SLB trades at $48.95, up 2.06% today, but technical indicators signal a bearish trend with key support at $48. The company reported revenue of $35.71B in 2025 with a net income margin of 8.53%, though margins have softened from prior years. Recent contract wins in Oman and Mozambique bolster long-term revenue visibility, while analyst consensus remains strongly bullish with an average price target of $64.58.
The stock presents a value opportunity given analyst optimism and strategic contract expansions, but faces headwinds from declining profit margins and bearish technical momentum. Earnings beats in recent quarters support fundamental strength, yet investors must weigh execution risks against the potential for significant upside relative to the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
